The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Carumonam     2-[[[(3S)-2- (aminocarbonyloxymethyl)-4- oxo...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Carumonam


Psychiatry related information on Carumonam

  • Carumonam inhibited Richmond-Sykes type Ia and Id beta-lactamases but was a poor inhibitor of type III enzymes [5].

High impact information on Carumonam


Chemical compound and disease context of Carumonam


Biological context of Carumonam


Anatomical context of Carumonam


Associations of Carumonam with other chemical compounds


Gene context of Carumonam


Analytical, diagnostic and therapeutic context of Carumonam

  • The pharmacokinetics of carumonam after a single 1,000-mg intravenous infusion (20 min) were evaluated in four groups of subjects who had various degrees of renal impairment: group 1, CLCR greater than 60 ml/min; group 2, CLCR = 30 to 60 ml/min; group 3, CLCR = 10 to 30 ml/min; and group 4, CLCR less than 10 ml/min) [20].
  • Serial plasma samples were collected after the first dose of the first regimen and the last dose of all three regimens and were analysed for carumonam by a specific HPLC method [21].
  • When E. coli O111 was grown in the presence of sub-MICs of the monocyclic beta-lactam antibiotic carumonam, however, the enzyme-linked immunosorbent assay titer increased from 1,280 to 81,920 [22].
  • Determination of the monocyclic beta-lactam antibiotic carumonam in plasma and urine by ion-pair and ion-suppression reversed-phase high-performance liquid chromatography [23].


  1. Comparative in vitro antimicrobial activity of carumonam, a new monocyclic beta-lactam. Smith, B.R., LeFrock, J.L., McCloskey, R.V., Donato, J.B., Weber, S.J., Joseph, W.S. Antimicrob. Agents Chemother. (1986) [Pubmed]
  2. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic. Imada, A., Kondo, M., Okonogi, K., Yukishige, K., Kuno, M. Antimicrob. Agents Chemother. (1985) [Pubmed]
  3. In vitro activity of carumonam (Ro 17-2301; AMA-1080) versus enteropathogenic and nonfermentative gram-negative rods and Legionella pneumophila. Hohl, P., von Graevenitz, A., Zollinger-Iten, J. Antimicrob. Agents Chemother. (1988) [Pubmed]
  4. In vitro activity of carumonam. Fass, R.J., Helsel, V.L. Antimicrob. Agents Chemother. (1985) [Pubmed]
  5. The in-vitro activity and beta-lactamase stability of carumonam. Neu, H.C., Chin, N.X., Labthavikul, P. J. Antimicrob. Chemother. (1986) [Pubmed]
  6. Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis. Konishi, K., Suzuki, H., Saruta, T., Deguchi, N., Fugono, T. Antimicrob. Agents Chemother. (1991) [Pubmed]
  7. Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Bérubé, D., Vallée, F., Panneton, A.C., Bergeron, M.G., LeBel, M. Antimicrob. Agents Chemother. (1988) [Pubmed]
  8. Carumonam versus ceftazidime for urinary tract infections. Edelstein, H., Oster, S., Cassano, K., McCabe, R. Antimicrob. Agents Chemother. (1988) [Pubmed]
  9. Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. Hoepelman, A.I., Bakker, L.J., Verhoef, J. Antimicrob. Agents Chemother. (1988) [Pubmed]
  10. Tigemonam activity against clinical isolates of Enterobacteriaceae and Enterobacteriaceae with known mechanisms of resistance to beta-lactam antibiotics. Nélet, F., Gutmann, L., Kitzis, M.D., Acar, J.F. J. Antimicrob. Chemother. (1989) [Pubmed]
  11. The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam. Jones, R.N., Barry, A.L., Thornsberry, C., Fuchs, P.C., Packer, R.R. Am. J. Clin. Pathol. (1986) [Pubmed]
  12. Comparative bactericidal activity of cefixime, carumonam, enoxacin and roxithromycin with those of other antibiotics against resistant Haemophilus influenzae including beta-lactam tolerant strains. Bergeron, M.G., Lavoie, G.Y., Boucher, F.D. J. Antimicrob. Chemother. (1987) [Pubmed]
  13. Comparative in vitro activity of carumonam (Ro 17-2301/AMA-1080), a new monobactam, and ceftriaxone against aerobic or facultative gram-negative isolates. Barclay, C.A., Iribarren, M.A., Goldberg, M., Traballi, C.A., Casellas, J.M. Chemotherapy. (1987) [Pubmed]
  14. Pharmacokinetics and dose recommendations of carumonam in renal failure. Koeppe, P., Höffler, D., Strobel, K. Arzneimittel-Forschung. (1987) [Pubmed]
  15. Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity. Shimizu, T., Souma, S., Nagakura, N., Masuzawa, T., Iwamoto, Y., Yanagihara, Y. Int. Arch. Allergy Immunol. (1992) [Pubmed]
  16. Effects of cephalosporins and carumonam on blood coagulation. Havel, M., Graninger, W., Korninger, H., Kurz, R., Müller, M., Horcher, E. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. (1987) [Pubmed]
  17. In vitro effects of monobactams on Legionella pneumophila. Yoshida, S., Mizuguchi, Y., Nikaido, Y. J. UOEH (1987) [Pubmed]
  18. Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Kita, Y., Fugono, T., Imada, A. Antimicrob. Agents Chemother. (1986) [Pubmed]
  19. Carumonam's in-vitro activity against gram-negative bacteria and its stability to their beta-lactamases. Raimondi, A., Mattina, R., Cocuzza, C.E. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. (1988) [Pubmed]
  20. Pharmacokinetics of carumonam in patients with renal insufficiency. Horber, F., Egger, H.J., Weidekamm, E., Dubach, U.C., Frey, F.J., Probst, P.J., Stoeckel, K. Antimicrob. Agents Chemother. (1986) [Pubmed]
  21. Multiple intravenous dose pharmacokinetic study of carumonam in healthy subjects. Patel, I.H., Soni, P.P., Portmann, R., Suter, K., Banken, L., Weidekamm, E. J. Antimicrob. Chemother. (1989) [Pubmed]
  22. Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5. Overbeek, B.P., Schellekens, J.F., Lippe, W., Dekker, B.A., Verhoef, J. J. Clin. Microbiol. (1987) [Pubmed]
  23. Determination of the monocyclic beta-lactam antibiotic carumonam in plasma and urine by ion-pair and ion-suppression reversed-phase high-performance liquid chromatography. Egger, H.J., Fischer, G. J. Chromatogr. (1987) [Pubmed]
WikiGenes - Universities